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AbstrACt
Introduction Non-specific genital infection (NSGI; 
non-Chlamydia trachomatis, non-Neisseria gonorrhoeae-
associated urethritis) is a common diagnosis in 
symptomatic heterosexual men attending UK sexual health 
clinics (SHCs). but little is known about the psychosocial 
impact of this diagnosis.
Methods We conducted an observational study among 
symptomatic heterosexual men attending SHCs to evaluate 
the psychosocial impact of an NSGI diagnosis compared 
with a diagnosis of Chlamydia trachomatis (CT), Neisseria 
gonorrhoeae or no abnormalities detected focusing on 
the feasibility of our study methodology. Participants 
completed a computer-assisted self-interviewing (CASI) 
including two validated measures of psychosocial impact: 
the EQ-5D-5L health-related quality of life and Rosenberg 
Self-Esteem Scale, before diagnostic testing and 2 weeks 
after receiving test results (follow-up 1 (FU-1)) and a 
qualitative interview. We compared scores between 
diagnostic groups using paired t-tests, qualitative data 
were analysed thematically and feasibility was assessed 
by process analysis.
results 60 men completed the baseline CASI (75% 
response rate). 46 (76.6%) were eligible for follow-up; 
11/46 (23.9%) completed the follow-up CASI, and 3/11 
(27.3%) completed the qualitative interview. 81.7% of all 
participants left CASI feedback at baseline: 73.5% reported 
the questionnaire as ‘fine’ or ‘very good’. Qualitative 
interview participants reported the study was acceptable. 
Compared with baseline, among patients completing FU-
1, only patients with a diagnosis of NSGI (p<0.05) or CT 
(p<0.05) showed increased EQ-5D-5L Index, whereas 
patients with a diagnosis of NSGI (p=0.05) showed 
decreased mean Rosenberg Self-Esteem Scale score.
Conclusions Although most participants indicated study 
acceptability at baseline, and we employed measures 
to increase retention (CASI questionnaires, reminder 
messages and a focus on men’s health), we experienced 
high loss to follow-up. We found that heterosexual men 
attending SHCs with symptoms of urethritis experience 
both positive and negative psychosocial impacts 
following their clinic attendance, which warrants further 
investigation.
IntroduCtIon  
Non-specific genital infection (NSGI) or, 
non-Chlamydia trachomatis (non-CT), non-Neis-
seria gonorrhoeae-associated urethritis (NGU), 
is the third most frequently diagnosed condi-
tion in heterosexual men attending sexual 
health clinics (SHCs) in the UK, with 30 381 
cases/year compared with Chlamydia tracho-
matis (CT) (42 483/year) and first presenta-
tion of genital warts (32 656/year).1 NSGI is 
a diagnosis of exclusion; men with urethral 
symptoms are screened with urethral micros-
copy in SHCs, and if this demonstrates 
urethritis with no gonococci, a provisional 
diagnosis of NGU is made.2 If urinary nucleic 
acid amplification tests (NAATs) sent for NG 
strengths and limitations of this study
 ► This study presents the first data investigating the 
psychosocial impacts of the common diagnosis of 
non-specific genital infection in heterosexual men 
attending sexual health clinics.
 ► This study used both validated scales and qualitative 
interviews to assess psychosocial impact.
 ► We used computer-assisted self-interviewing to col-
lect data on psychosocial impact as this has been 
shown to improve data quality in sensitive topics.
 ► The study was small and was conducted in two 
London sexual health clinics, which may limit the 
generalisability of our results.
 ► There was high loss to follow-up after baseline, 
which may have biased our results.
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and CT are both negative, the diagnosis is recorded as 
NSGI.
Although a common condition, NSGI remains poorly 
understood. NSGI can be caused by a variety of sexually 
transmitted infections (STIs), including Mycoplasma geni-
talium and Trichomonas vaginalis, which are not routinely 
tested for in SHCs, and many cases have an uncertain aeti-
ology.2 Microscopy, on which the diagnosis rests, has poor 
specificity for known causes of urethritis3 and is subject 
to considerable observer variation.4 National guidelines 
recommend that men diagnosed with NGU are informed 
they may have an STI, given same day empirical antibi-
otics, advised their partners should attend for STI testing 
and empirical treatment and to abstain from sex until 
treatment is completed.2 Men usually receive CT/NG 
NAAT results within 8 days.5 Following first-line anti-
biotics for NSGI, 10%–20% of men return because of 
persistent symptoms.6 7
Men who undergo STI testing and are diagnosed with 
an STI report negative impacts on their psychosocial well-
being, including feelings of stigma8–10; however, to our 
knowledge, there are no published data on the psycho-
social impact of NSGI diagnosis among men. Stigma has 
been shown in men to be associated with a delay in testing 
for STIs and decreased willingness to notify their casual 
partners of their STI diagnosis.11 Studies on psychosocial 
impact, partner notification and quality of life impact 
have predominantly been carried out in women,9 12–14 
with few studies recruiting men. A greater understanding 
of the degree and nature of psychosocial impacts of a 
diagnosis of an STI, or a ‘presumed STI’ such as NSGI, 
in men, is important to optimise interventions, including 
partner notification and risk-behaviour modification, 
which aim to reduce the negative impact of STIs, such as 
complications of infection.
Men are reportedly poor users of health services, 
largely due to culturally dominant ideals of masculinity 
that equate illness with weakness, which may impede 
care seeking.15–18 In sexual healthcare, there has tradi-
tionally been a focus on female reproductive health,19 
and this may further discourage male attendance.19 20 
However, men are willing to respond openly to questions 
about their sexual health, particularly when enquiries are 
focused specifically on men’s needs.19 21
We decided to focus on heterosexual men in this study 
as there are important differences between men who have 
sex with men (MSM) and men who have sex exclusively 
with women (MSEW) in their access of SHC services, 
reported sexual health risks, their own perception of risk 
of STIs and sexual health and well-being outcomes,22 
suggesting that their experience of diagnosis of a genital 
infection may also be different. Due to these important 
differences between MSM and MSEW, we decided that 
psychosocial impacts of an STI diagnosis in MSM merited 
studying separately.
Because of a lack of models to measure the psychoso-
cial impact of an NSGI diagnosis among men, and the 
potential difficulty in recruiting and retaining this group 
in sexual health studies, we designed a small-scale longi-
tudinal mixed-method feasibility study to inform on our 
research methods and better understand the psychoso-
cial and health-related quality of life (HRQoL) status of 
symptomatic heterosexual men before and after receiving 
a diagnosis of NSGI, CT, NG or ‘nothing abnormal 
detected’ (NAD).
Methods
study design
We conducted an observational, longitudinal study in 
symptomatic heterosexual men using patient completed 
questionnaires assessing HRQoL and psychosocial status 
before and after receiving STI test results and individual 
qualitative interviews to evaluate experiences at the SHC 
and acceptability of study methods.
Eligibility criteria were: heterosexual men presenting 
with urethral symptoms (dysuria, discharge or urethral 
discomfort) and aged ≥16 years at either of two partici-
pating London SHCs between September and October 
2016. We excluded men who were asymptomatic, not 
available for follow-up and who were unable to under-
stand English.
Following informed consent, participants were invited 
to complete a baseline computer-assisted self-interviewing 
(CASI) assessing psychosocial and HRQoL status in clinic 
prior to consultation, a follow-up CASI after receipt of all 
test results 1–2 weeks after baseline (follow-up 1 (FU-1)) 
and a qualitative interview 2–4 weeks after baseline 
(follow-up 2 (FU-2)).
The participant pathway is detailed in figure 1. After 
completion of the baseline CASI, any participants diag-
nosed with an STI other than CT, NG or NSGI, or who did 
not have both urethral microscopy and urinary NAATs, 
were withdrawn from the study. Once participants were 
notified of their NAAT CT/NG results by the SHC (phone 
call/text message), the research team texted participants 
an electronic link to the FU-1 CASI.
CASIs were optimised for web-enabled devices 
including smartphones. We offered participants the 
choice to complete CASIs using their own device or a 
study tablet device and use of a private room in clinic. 
Study staff sent ≤2 text message reminders for each 
follow-up. Participants who did not complete FU-1 were 
considered ineligible for FU-2. Participants received gift 
voucher reimbursements: £5 (baseline), £10 (FU-1) and 
£20 (FU-2).
We categorised participants into four diagnostic groups 
based on microscopy and NAAT results: NSGI (NGU 
diagnosis on urethral microscopy and CT/NG NAATs 
negative); NG (NG on urethral microscopy and/or posi-
tive NAAT); CT (positive NAAT); and NAD (no urethritis 
on microscopy and CT/NG NAATs negative).
Questionnaire design
At both baseline and FU-1 CASIs, the EQ-5D-5L, a generic 
measure of HRQoL,23 and the Rosenberg Self-Esteem 
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Figure 1 Patient pathway. NG, Neisseria gonorrhoeae.
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Scale (RSES),24 a measure of potential stigmatising 
effects of screening for STIs, were used. The EQ-5D-5L 
is the preferred utility measure recommended by the UK 
National Institute for Health and Clinical Excellence22 
and has five dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Weighted UK 
preference values are linked to the self-reported health 
state scores for a 0–1 Index value, where 0 is death and 1 
is perfect health. The RSES is widely used in social science 
research to measure self esteem; it uses a scale of 0–30, 
where a score less than 15 may indicate low self esteem, 
15–25 normal self-esteem and 25–30 high self-esteem.
In addition, the baseline CASI included the Multidi-
mensional Scale of Perceived Social Support (MSPSS)25 
to assess coping resources. The MSPSS is widely used 
to assess perceived social support and consists of three 
domains: family, friends and significant others. Mean 
MSPSS scores from 1 to 2.9 may be considered low 
support; 3–5 moderate support and 5.1–7 high support.26
We collected data on sociodemographics in the base-
line CASI and current relationship status in both the 
baseline and FU-1 CASI. In the FU-1 CASI, we included a 
panel of questions previously developed to assess impact 
of CT diagnosis in women,13 which we modified for use 
in men by removing a pregnancy-related question. Partic-
ipants were asked to indicate acceptability of the CASIs 
(free-text response) at baseline and FU-1 (online supple-
mentary appendices 1–3).
Patient and public involvement
There was no formal patient and public involvement 
informing the research question or study procedures. 
Clinician experiences with patients diagnosed with 
NSGI informed the need for investigation of the poten-
tial harms resulting from this diagnosis. The results have 
been disseminated via the study groups’ community advi-
sory group (formed after the research was planned and 
implemented).
sample size
As this was a feasibility study with no precedent, no formal 
sample size could be calculated. We planned to approach 
100 patients at baseline as a convenience target, and 
assuming approximately 50% refusal, we expected 50–60 
patients to be enrolled and estimated ~50% attrition at 
each follow-up.
outcome measures
Primary outcome
Qualitative and quantitative process data on recruitment 
and retention rates at baseline and follow-up to inform 
on feasibility of study design. Evaluation of potential rele-
vance of questions validated in other populations for men 
diagnosed with NSGI.
Secondary outcomes
Percentage change from baseline to FU-1 in mean 
EQ-5D-5L Index value, and mean RSES value in men 
diagnosed with CT, NG, NSGI or NAD.
We did not have prior expectations about different 
impacts of these diagnoses, and as there are no studies 
comparing the impact of CT to NG or NSGI in men, 
this was exploratory. We were interested in investigating 
whether NSGI was perceived as a benign diagnosis or 
whether it elicited negative psychosocial impacts that 
have been reported in men diagnosed with STIs such as 
CT.10
data analysis
Questionnaire data
For all eligible men, RSES score, MSPSS score and 
EQ-5D-5L Index value were calculated according to 
published methods.23–25 27
For men in each diagnostic category, paired t-tests were 
used to compare mean values for the EQ-5D-5L Index, 
RSES and MSPSS at baseline and to compare differences 
in mean values for EQ-5D-5L Index and RSES score, from 
baseline to follow-up.
To test for non-response bias, we compared sociodemo-
graphic data of those who completed both baseline and 
follow-up to those who were lost to follow-up (LTFU), 
using Pearson’s χ2 tests and Kruskal-Wallis tests. Statis-
tical significance was set at p<0.05. Statistical analysis was 
carried out using STATA V.13.1.
Qualitative data
Audio recordings were transcribed, and transcripts were 
checked for accuracy against the recording. Cleaned 
transcripts were then imported into NVivo (V.10, 2012) 
for analysis. Two researchers assigned themes to text 
independently, with discrepancies resolved by consensus 
before reporting final themes. All names of participants 
presented here are pseudonyms.
results
We approached 80 patients, of whom 60 (75%) enrolled 
and completed the baseline CASI. Forty-six (76.6%) were 
eligible for follow-up; of these, 11 (23.9%) completed 
the FU-1 CASI, and 3 of these (27.3%) completed FU-2 
(figure 2). Final diagnoses among all eligible participants 
(n=46) were: CT: 7 (15.2%); NG: 2 (4.3%); NSGI: 23 
(50%); and NAD: 14 (30.4%), and among participants 
who completed FU-1 (n=11) were: CT: 4 (36.4%); NSGI: 
4 (36.4%); and NAD: 3 (27.3%). None of the participants 
diagnosed with NG completed FU-1. Two participants 
with NSGI and one with NAD completed FU-2. Clinical 
records indicated that all participants were notified of 
their CT/NG NAAT diagnosis within 7 days of completing 
baseline.
Men who reported urethral symptoms but had no abnor-
malities on urethral sample testing and negative CT and 
NG results (categorised as NAD) had a variety of non-STI 
causes for their symptoms diagnosed, including irritant 
or Candida balanitis, lower urinary tract symptoms, which 
were likely prostatic in origin, non-infectious genital pain 
syndromes and symptoms secondary to urethral trauma.
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Participants’ sociodemographic factors at baseline are 
presented in table 1. Most were between 25 and 35 years 
old (60.9%), and over half reported their ethnicity as 
non-white (52.2%). A percentage of 80.4 indicated they 
were not in a relationship, and many had previously been 
diagnosed with STIs (30.4% NGU, 28.3% CT, 13.0% 
genital herpes or warts and 8.7% NG).
Pearson’s χ2 tests and Kruskal-Wallis test results for 
non-response bias were not statistically significant so we 
assumed data were missing at random. We compared 
participants who completed FU-1 to those LTFU by 
employment, age, education, ethnicity and current 
relationship status; none of these comparisons showed 
significant differences.
Process evaluation
All patients who completed the baseline CASI did so 
using the study tablet device in a private room in the 
clinic. Participants completed the baseline CASI in about 
5 min. All participants completed the follow-up CASI at 
home on a participant-owned device.
CASI feedback suggested good acceptability: of the total 
60 who completed the baseline CASI, 81.7% left feed-
back, of whom 73.5% reported that the questionnaire was 
Figure 2 Enrolment and follow-up chart.
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Table 1 Sociodemographic characteristics of enrolled participants at Baseline by final diagnosis
CT n (%) NG n (%) NSGI n (%) NAD n (%) Total n
Age (year)
  <24 5 (71.43) 1 (50) 5 (21.74) 3 (21.43) 14
  25–35 2 (28.57) 1 (50) 17 (73.91) 8 (57.14) 28
  >35 0 (0) 0 (0) 1 (4.35) 3 (21.43) 4
Ethnicity
  White 5 (71.43) 0 (0) 10 (43.48) 6 (42.86) 21
  Asian 0 (0) 1 (50) 2 (8.7) 2 (14.29) 5
  Black 1 (14.29) 1 (50) 10 (43.48) 2 (14.29) 14
  Other 1 (14.29) 0 (0) 1 (4.35) 3 (21.43) 5
  Prefer not to say 0 (0) 0 (0) 0 (0) 1 (7.14) 1
Age at leaving full-time education
  16 years or less 0 (0) 0 (0) 1 (4.35) 3 (21.43) 4
  17 or 18 years 0 (0) 0 (0) 6 (26.09) 0 (0) 6
  19 years or over 4 (57.14) 0 (0) 14 (60.87) 10 (71.43) 28
  Still in full-time 
education
3 (42.86) 2 (100) 2 (8.7) 1 (7.14) 8
Highest educational achievement
  No qualifications/
no formal 
qualifications
1 (14.29) 0 (0) 1 (4.35) 0 (0) 2
  1–5 General 
Certificates 
of Secondary 
Education 
(GCSEs)
0 (0) 0 (0) 3 (13.04) 2 (14.29) 5
  Two or more 
A-levels or 
equivalent
1 (14.29) 1 (50) 4 (17.39) 2 (14.29) 8
  Bachelor’s degree 
or equivalent and 
higher
5 (71.43) 1 (50) 13 (56.52) 8 (57.14) 27
  Other 0 (0) 0 (0) 2 (8.7) 2 (14.29) 4
Do you have any long-standing condition?
  Yes 1 (14.29) 0 (0) 1 (4.35) 2 (14.29) 4
  No 6 (85.71) 2 (100) 22 (95.65) 12 (85.71) 42
Previously diagnosed with CT?
  Yes 4 (57.14) 1 (50) 7 (30.43) 1 (7.14) 13
  No 3 (42.86) 1 (50) 16 (69.57) 13 (92.86) 33
Previously diagnosed with NG?
  Yes 0 (0) 2 (100) 2 (8.7) 0 (0) 4
  No 7 (100) 0 (0) 21 (91.3) 14 (100) 42
Previously diagnosed with NGU?
  Yes 2 (28.57) 0 (0) 9 (39.13) 3 (21.43) 14
  No 5 (71.43) 2 (100) 14 (60.87) 11 (78.57) 32
Previously diagnosed with herpes/warts?
  Yes 3 (42.86) 0 (0) 1 (4.35) 2 (14.29) 6
  No 4 (57.14) 2 (100) 22 (95.65) 12 (85.71) 40
Relationship status
Continued
 o
n
 16 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-018213 on 30 June 2018. Downloaded from 
7Hill-Tout R, et al. BMJ Open 2018;8:e018213. doi:10.1136/bmjopen-2017-018213
Open access
‘fine’ or ‘very good’ in a free-text box at the end of the 
questionnaire.
Participants suggested improvements to the study 
during qualitative interviews: to use the research as a tool 
for health promotion and to make CASI questions more 
clearly relevant to sexual health. Insight into LTFU was 
provided by one participant, who said he might not have 
continued with the study if he had received a positive STI 
diagnosis:
I reckon if my tests had not come back the way I want-
ed them to, I probably wouldn’t have done this last 
[follow-up]. … I might’ve still said, ‘Yes, let’s do it.’ I 
don’t know but I… Just sitting here, thinking about 
it now, I probably wouldn’t complete the rest of it. 
(Lucas, NAD diagnosis)
CAsI analysis
Distributions of participants’ psychosocial scores at base-
line by final diagnosis are shown in table 2. At baseline 
(table 2A) participants ultimately diagnosed with NG 
had significantly lower (p≤0.050) mean MSPSS scores 
(indicating lower social support), compared with men 
ultimately diagnosed with NSGI or NAD, as well as 
lower scores as compared with those diagnosed with CT 
(p=0.059). Participants with NG also had lower mean 
RSES scores (indicating lower self-esteem) at baseline 
as compared with those with NSGI (p=0.035). EQ-5D-5L 
Index value at baseline did not vary significantly between 
diagnosis groups.
We found men with NSGI and CT showed a significant 
increase in mean EQ-5D-5L Index value (indicating better 
HRQoL) between baseline and FU-1 (+17% ([p=0.006) 
and +219% (p=0.005), respectively) (table 2B). There 
was no change in mean EQ-5D-5L Index value for men 
diagnosed with NAD. In contrast, we found decreases 
in mean RSES scores from baseline to FU-1 in men with 
NSGI (−30%, p=0.05).
Participants who reported that they had been diag-
nosed with an infection (n=5, four with a final diagnosis 
of CT and one with NSGI) completed a panel of ques-
tions in the FU-1 CASI to assess their feelings about 
their diagnosis. All participants reported that they were 
‘not worried as it is curable’ and did not think the diag-
nosis would change how their friends thought about 
them, but only one participant (diagnosed with CT) 
reported he had talked to his friends about his diag-
nosis. All participants reported concern that they might 
get the infection again, and the majority of those with 
a CT diagnosis (75%) reported concern about expo-
sure to other STIs, feeling ‘dirty’ and embarrassed, 
being scared to tell their partners about their diagnosis 
and worried that their partners thought they had been 
unfaithful.
Qualitative analysis
In interviews, participants compared different STIs as a 
way to contextualise their level of concern about their 
own diagnosis. For one participant, his main concern was 
the possibility of being diagnosed with HIV:
Look, to be honest with you, the key one everyone re-
ally wants to know about is HIV … all the other ones 
are treatable quite easily… (Lucas, NAD diagnosis)
There were several points within the interviews where 
participants expressed concern at being diagnosed with 
an infection they did not know about, indicating that 
non-specific diagnoses may cause negative impact:
…to be honest, I’m a little bit worried about this be-
cause there is no name of the new bacteria, so we 
don’t know if it’s dangerous or not… (Liam, NSGI 
diagnosis)
CT n (%) NG n (%) NSGI n (%) NAD n (%) Total n
  Married and living 
with wife
0 (0) 0 (0) 1 (4.35) 2 (14.29) 3
  Cohabiting but 
not married
1 (14.29) 0 (0) 2 (8.7) 2 (14.29) 5
  Separated, 
divorced or 
widowed
0 (0) 0 (0) 1 (4.35) 0 (0) 1
  Single (ie, never 
married)
6 (85.71) 2 (100) 19 (82.61) 9 (64.29) 36
  Prefer not to say 0 (0) 0 (0) 0 (0) 1 (7.14) 1
Break up in the last 30 days
  Yes 1 (14.29) 0 (0) 3 (13.04) 5 (35.71) 9
  No 6 (85.71) 2 (100) 20 (86.96) 9 (64.29) 37
CT, Chlamydia trachomatis; NAD, nothing abnormal detected; NG, Neisseria gonorrhoeae; NGU, non-Neisseria gonorrhoeae (non-NG)-
associated urethritis; NSGI, non-specific genital infection.
Table 1 Continued 
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Among the two interview participants diagnosed with 
NSGI, one described anxiety following his presumptive 
CT diagnosis in clinic. He was in a long-term monoga-
mous relationship and so was not expecting an STI 
diagnosis:
My heart’s racing. I’m thinking, ‘but how, I can’t.’ … 
I just had a lot of thoughts in my head. … And I told 
[the doctor], ‘I can’t. I don’t know how I would have 
this.’ He’s saying, ‘Well, whatever you have, it’s sexual-
ly transmitted.’ I said, ‘But it can’t be.’ So of course I 
start getting things in my head. (Jacob, NSGI diagno-
sis) (online supplementary appendix 4)
dIsCussIon
In this small observational feasibility study, we assessed 
patient reported self-esteem and HRQoL using vali-
dated scales in heterosexual men presenting to SHCs 
with urethral symptoms, before undergoing STI testing 
and after receiving all test results. This is the first study 
to investigate the HRQoL and psychosocial impact of a 
curable STI diagnosis in symptomatic men attending 
SHCs, using validated scales, and is one of the few avail-
able with data on STIs and EQ-5D-5L.28
We found increased EQ-5D-5L Index value (indicating 
increased HRQoL) in men diagnosed with NSGI or CT 
from baseline to FU-1. Published studies have reported 
that some men diagnosed with CT reported a lack of 
concern regarding the diagnosis as they perceive CT as 
a relatively minor infection.8 10 14 29 This was supported 
by one of our qualitative interview participants. The 
increases we found in the EQ-5D-5L Index value may 
reflect decreases in the anxiety and pain/discomfort 
domains of the scale from just prior to consultation at 
baseline to receipt of all test results in FU-1. Shoveller 
et al30 reported that the majority of men diagnosed with 
an STI in SHCs had reported feeling anxious waiting for 
potentially bad news, and so this finding may reflect that 
men found relief following treatment and explanation of 
their symptoms and receiving negative results for more 
serious infections such as HIV. Due to our small sample 
size, we were unable to find significant associations 
between participant satisfaction with their clinic visit and 
relief from symptoms and infection status in our CASI 
FU-1 data.
Furthermore, in men diagnosed with NSGI, we found 
decreased mean RSES score (indicating decreased 
self-esteem) from baseline to approximately 1 week after 
receiving all STI test results. These findings support data 
from previous qualitative studies where men diagnosed 
with an STI in an SHC reported negative psychosocial 
impacts including stigma, anxiety, shame, isolation, 
concerns regarding relationships, a loss of social status, 
vulnerability, a lack of privacy and fear of STI testing, 
particularly urethral swab testing.8 10 30–32 We did not 
find a decrease in self-esteem in men diagnosed with CT, 
which might suggest that NSGI is perceived differently to 
CT. In our qualitative interviews, participants with NSGI 
reported concerns regarding the uncertainty of the diag-
nosis and fear of the impact of a possible STI diagnosis on 
their relationships; these factors may be important in the 
observed decreased self-esteem in these men.
limitations
Our choice of HRQoL tool, the EQ-5D-5L, may not be 
sensitive enough to detect impacts caused by the diag-
nosis of CT, NG or NSGI, which are unlikely to cause 
problems in at least two of the five domains: mobility and 
self-care. Studies investigating HRQoL and sexual health 
have found few significant differences with comparator 
groups using generic QoL instruments alone.33 STI-spe-
cific HRQoL and psychosocial impact tools have been 
developed for genital herpes and genital warts,34–36 and 
several studies have now also combined both EQ-5D-5L 
and STI-specific tools.37–40
Our study did not include asymptomatic men; hence, 
we cannot exclude the possibility that the negative impact 
on self-esteem observed with men was not related to 
being symptomatic or undergoing genital examination 
and a urethral swab.10 30 32 We suggest that future studies 
consider including both symptomatic and asymptom-
atic men to better evaluate the impact of the experience 
of having symptoms, genital examination and invasive 
testing on psychosocial well-being and self-esteem.
Although the RSES and the EQ-5D-5L scales we used 
in this study have been validated in men and women, the 
panel of questions used to assess men’s feelings about a 
diagnosis of CT or NSGI in the FU-1 CASI has not been 
validated in men or for non-CT STI diagnoses. In addi-
tion, we assessed psychosocial and HRQoL impact at a 
single time point, which does not measure durability of 
the observed decrease in self-esteem in this population, 
and data suggest psychosocial impact of STI diagnoses 
may decrease over time.41
We received feedback from our participants that some 
of the wording of questions on our CASIs did not appear 
to be directly relevant to our study aims. Future studies 
should ensure that data collection measures use terms that 
are clear and familiar to participants, possibly through 
development of questionnaires with focus groups. Some 
participants requested that future studies offer research 
participants material on health promotion, that is, mate-
rial on the infection they were diagnosed with and how to 
reduce risk of infection.
Despite concerns that the target group of heterosexual 
men attending SHCs would be difficult to recruit,42 we 
found 75% of men were happy to enrol in this study. This 
should encourage researchers to investigate views from 
this group regarding STI diagnosis and screening. A study 
investigating the psychosocial experiences of patients 
attending a clinic, which recruited men and women diag-
nosed with an STI from an SHC, reported a recruitment 
rate of 33%31 and involved 10 interviews lasting between 
20 min and 45 min each. Our higher baseline recruitment 
rate may be due to the use of CASI interviewing, fewer 
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interviews or because patients were recruited before they 
had any diagnosis made.
One of the difficulties associated with conducting longi-
tudinal studies is attrition. In our study, of those eligible 
for follow-up, 24% overall completed the follow-up CASI, 
25% of those with a diagnosis of NSGI, CT or NG and 
21% of those with NAD. A longitudinal questionnaire 
study investigating community screening for CT reported 
follow-up rates of over 60%; however, eligibility for 
follow-up excluded those with positive STI test results, 
and 60% of the sample was female, reflecting the higher 
response rate among women.12 Our study’s qualitative 
component had a follow-up rate of 27% overall, 25% in 
those who had any positive diagnosis and 33% in those 
with NAD. By comparison, a study including men, inves-
tigating patient views on CT screening recruited 6.6% of 
those who completed the baseline questionnaire to a qual-
itative interview, which was below their target of 10%.43
We embedded several mechanisms in our study to 
improve participant acceptability and retention. Privacy 
when completing sensitive questions has been shown to 
improve participant acceptability for revealing poten-
tially stigmatising information44; we used a web-based 
CASI and the option for participants to self-complete 
the questionnaire in a private room in the clinic. Poten-
tial research participants, and men specifically, are more 
likely to participate in research that represents their 
concerns19 21 45; eligibility for this study was restricted to 
those patients who were likely to be diagnosed with an 
STI and focused on the impact of those diagnoses. In 
addition, reimbursements have been shown to play a part 
in increasing enrolment and retention in research45 46; we 
reimbursed participants in increasing amounts to reflect 
the time and effort we estimated were necessary to 
complete the research. Despite these mechanisms, and 
positive participant feedback on the baseline CASI and 
in our qualitative interviews, we experienced high LTFU. 
High LTFU resulted in low numbers of respondents 
within diagnostic categories, which meant we were unable 
to adjust our analysis for common confounders, such as 
education and socioeconomic status, known to be asso-
ciated with gonorrhoea.47 48 This may be a source of bias 
in our results. We did not find significant differences 
between groups in terms of non-response bias and other 
characteristics; however, this is not surprising as the power 
to detect differences between groups is greatly affected by 
sample size, and our study included a small number of 
participants. Recruiting larger numbers of participants in 
future studies will increase the statistical power to detect 
any important differences between groups.
We explored potential correlates and causes for LTFU 
within our dataset. Men’s socioeconomic status and age 
have been seen to affect both their knowledge of and 
interaction with health services.20 However, we did not 
find significant differences in these factors between those 
LTFU and those who completed FU-1. One participant 
indicated in qualitative interview that if he had received 
a positive STI diagnosis, it was unlikely that he would 
have agreed to continue with the research. This may give 
insight into why no patients receiving a positive CT or NG 
diagnosis agreed to FU-2.
We had planned to further explore study acceptability 
by inviting participants who failed to complete FU-1 to 
qualitative interviews; however, we followed research 
ethics committee recommendations to consider that 
these participants had passively withdrawn from the study 
and refrained from inviting them to FU-2. Yet, qualitative 
and quantitative methods of data collection are viewed 
differently by respondents.49 50 One participant described 
the difference between his experiences completing the 
survey and participating in an interview:
…when I’m sitting here with you, obviously it’s just 
me and you and you’ve got my hundred percent full 
attention, haven’t you? But then when I’m sitting 
at my desk at work, trying to complete a survey and 
there’s other things going on and people asking me 
questions and ‘can you do this, can do you that’; it’s 
different. (Lucas, NAD diagnosis)
Although we cannot know if participants who did not 
complete FU-1 would have participated in a qualita-
tive interview if they had been invited, one participant 
left feedback on the baseline CASI indicating he would 
have preferred to elaborate on his answers, and several 
participants informally conveyed this to the researcher at 
baseline. Research has shown that one unique benefit of 
qualitative interviews is that it provides participants with 
an opportunity to expand or contextualise issues.49 50 In 
addition, the insights we gained from the limited qualita-
tive interviews we conducted indicate the potential useful-
ness of this method to understand nuances of acceptability 
that may lead to reduced LTFU. We therefore recommend 
that future feasibility studies include qualitative compo-
nents as a means to allow participants, including those 
who fail to complete survey questionnaires, to provide 
important feedback on study methods. Future studies 
could also consider offering a qualitative interview at the 
point of recruitment, not only at follow-up, to widen the 
possibility of a qualitative exploration among participants 
who do not find the CASI questionnaire acceptable.
The issue of gender concordance between partici-
pants and interviewers/researchers has been discussed 
in the literature,51 and the fact that our study recruiter 
was female may have affected recruitment and retention. 
A study investigating attitudes to Viagra in heterosexual 
Hispanic men, using telephone qualitative interviews, 
found that changing from female to male recruiters and 
data collectors increased their recruitment.42 Participants 
in our study were offered the option of a male or female 
interviewer but may not have felt comfortable with asking 
for a particular interviewer and so this may not have been 
sufficient to reduce the potential impact of gender discor-
dance on acceptance of the invitation to an interview in 
our study. We suggest future studies involving qualitative 
interviews should consider the gender of recruiters and 
interviewers.
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ConClusIons
Our study found that heterosexual men with urethral 
symptoms may experience a range of psychosocial and 
HRQoL impacts following SHC attendance and STI 
testing. More work is needed to investigate the most 
appropriate methodology for investigating sexual health 
and QoL, particularly around choosing between condi-
tion specific and generic measures, and reducing loss to 
follow-up in longitudinal studies. Future research in this 
area is needed to test the generalisability of our findings 
as to whether there are significant psychosocial harms of 
giving presumptive and non-specific diagnoses.
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